<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02484807</url>
  </required_header>
  <id_info>
    <org_study_id>EPIC-01</org_study_id>
    <nct_id>NCT02484807</nct_id>
  </id_info>
  <brief_title>Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAH</brief_title>
  <acronym>EPIC</acronym>
  <official_title>Effect of Pharmacologic Interaction Between Endothelin-Receptor-Antagonists and Phosphodiesterase-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients Wih Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The development of disease-targeted medication for the treatment of pulmonary arterial
      hypertension (PAH) has significantly improved within the last years, leading to the
      development of 10 approved agents. Combination treatment with Endothelin-Receptor-Antagonists
      (ERA) and Phosphodiesterase-Type-5-Inibitors (PDE-5-Inhibitor) has become increasingly
      important for the treatment of PAH. In a recent press release, the results of the AMBITION
      study reported that an upfront combination treatment immediately after diagnosis leads to a
      delayed disease progression [4]. Thus, the question if there is a clinically relevant
      pharmaco-dynamic drug-drug interaction is of rising interest.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mechanisms of action Three ERAs have been approved for the treatment of PAH including the
      dual inhibitors Bosentan and Macitentan and the selective Endothelin Receptor type A
      inhibitor (ETA-Inhibitor) Ambrisentan. The dual antagonists inhibit both ETA- and the type B
      (ETB)-receptor, while the selective antagonist only affects the ETA-receptor [2]. The
      physiologic ligand of the receptors is Endothelin-1, which binds to the ETA-receptor and
      causes vasoconstriction and proliferation of the vascular smooth muscle cells. The binding to
      the ETB-receptor leads to an endogenous production of NO and prostacyclin in the endothelial
      cells.

      PDE-5-Inhibitors include the two substances Sildenafil and Tadalafil. They inhibit the
      degradation of cyclic guanosine monophosphate (cGMPs), which triggers the vasodilative effect
      of endothelial NO.

      Interaction There is evidence for the pharmacokinetic interaction (inhibition / induction of
      critical targets of drug metabolism and drug distribution) of both substance classes: the
      PDE-5-Inhibitors Sildenafil and Tadalafil are mainly eliminated in the liver by the hepatic
      enzyme Cytochrom-P450-Oxygenase type 3A4 (CYP3A4). The dual inhibitor Bosentan is both a
      substrate and an inductor of the Cytochrom-P450-Oxydase type 3A4 and type 2C9 [5,6].

      It has already been shown in an in vivo-study, that simultaneous application of
      PDE-5-Inhibitors and Bosentan leads to a systemic reduction of the PDE-5-Inhibitor
      concentration of 40%, due to the CYP3A4-inducing effect of Bosentan [5]. Sildenafil, in
      contrast, leads to a decreased degradation of Bosentan in the liver with an approximately 50%
      increase in plasma leves. An anticipated result, especially when higher dosages of Sildenafil
      are applied, is the accumulation of Bosentan and reduction of Sildenafil levels.

      A recent in vitro-study has shown that Tadalafil may also serve as CYP3A4-inductor, while
      this effect has not been detected for Sildenafil [7].

      In contrast Macitentan which has been approved in 2013, has no clinically relevant
      CYP3A4-inducing effects. [8]. The in vitro-study has also detected a further interaction
      between ERAs and PDE-5-Inhibitors. Both PDE-5-Inhibitors Sildenafil and Tadalafil affect the
      transport molecules organic anion transporting polypeptides (OATPs), which are responsible
      for the hepatocellular intake of the dual ERA Bosentan. They also had a mild effect on the
      intake of Ambrisentan.

      Sildenafil is a potent inhibitor of OATPs, whereas Tadalafil shows only minor inhibition of
      OATPs [7]. Both Sildenafil and Tadalafil significantly reduce the intracellular concentration
      of Bosentan in the liver, leading to a reduced degradation of Bosentan. For Ambrisentan this
      effect seemed to be less pronounced [7]. Consequently, this mechanisms of action lead to
      higher ERA-levels and to decreased PDE-5-Inhibitor plasma concentrations in patients
      receiving combination treatment. The most distinct interaction is expected for the
      combination of Sildenafil (PDE-5-Inhibitor) and Bosentan (ERA).

      Up to now, the prevalence and role of this pharmacokinetic interaction for the clinical
      status and progression of the disease is not clear. Respective combination treatments have
      only been investigated in healthy male volunteers so far [5,9].
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characterisation of Medication Levels</measure>
    <time_frame>baseline vs. measurement after 3-6 months</time_frame>
    <description>comparison of different combination treatment arms (mean ± standard deviation), measurement of endothelin receptor antagonist plasma concentrations and PDE-5I plasma concentrations, results given es multiple of the expected mean plasma concentration (MOM). Due to technical setup measurement of plasma concentrations of macitentan was not possible.
The expected mean concentration ranges (MOM) refer to data extracted from published plasma concentration-time profiles measured during monotherapy with sildenafil, tadalafil, bosentan, and ambrisentan and served as comparative values. Each individually measured drug concentration was set in proportion to the expected mean concentration and expressed as a multiple of the expected mean (MoM), with values &lt;1 denoting lower and values &gt;1 higher values than the expected mean.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of Medication Adjustment</measure>
    <time_frame>baseline vs. measurement 3-6 months after switch</time_frame>
    <description>Change of medication serum levels after clinically indicated medication adaptation in patients who received Bosentan + Sildenafil in the beginning and changed the ERA to Macitentan
change of mean levels ± standard deviation
frequency of borderline medication serum levels or medication levels out of the therapeutic window The expected mean concentration ranges (MOM) refer to data extracted from published plasma concentration-time profiles measured during monotherapy with sildenafil, tadalafil, bosentan, and ambrisentan and served as comparative values. Each individually measured drug concentration was set in proportion to the expected mean concentration and expressed as a multiple of the expected mean (MoM), with values &lt;1 denoting lower and values &gt;1 higher values than the expected mean.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevance 6 Minute Walking Distance</measure>
    <time_frame>baseline vs. measurement 3-6 months after switch</time_frame>
    <description>Changes of medication levels after adjustment of combination therapy if clinically indicated
correlation with clinical routine parameters indicating clinical disease status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevance NTproBNP</measure>
    <time_frame>baseline vs. measurement after 3-6 months</time_frame>
    <description>Changes of medication levels after adjustment of combination therapy if clinically indicated
correlation with clinical routine parameters indicating clinical disease status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevance Echocardiography Systolic Pulmonary Arterial Pressure (sPAP)</measure>
    <time_frame>baseline vs. measurement after 3-6 months</time_frame>
    <description>Changes of medication levels after adjustment of combination therapy if clinically indicated
correlation with clinical routine parameters indicating clinical disease status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevance Echocardiography Tricuspid Annular Plane Systolic Excursion (TAPSE)</measure>
    <time_frame>baseline vs. measurement after 3-6 months</time_frame>
    <description>Changes of medication levels after adjustment of combination therapy if clinically indicated
correlation with clinical routine parameters indicating clinical disease status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevance Blood Gas Analysis Oxygen Saturation</measure>
    <time_frame>baseline vs. measurement after 3-6 months</time_frame>
    <description>Changes of medication levels after adjustment of combination therapy if clinically indicated
correlation with clinical routine parameters indicating clinical disease status</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Actual">125</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Bosentan + Sildenafil</arm_group_label>
    <description>Combination treatment with Bosentan + Sildenafil at baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bosentan + Tadalafil</arm_group_label>
    <description>Combination treatment with Bosentan + Tadalafil at baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ambrisentan + Sildenafil</arm_group_label>
    <description>Combination treatment with Ambrisentan + Sildenafil at baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ambrisentan + Tadalafil</arm_group_label>
    <description>Combination treatment with Ambrisentan + Tadalafil at baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Macitentan + Sildenafil</arm_group_label>
    <description>Combination treatment with Macitentan + Sildenafil at baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Macitentan + Tadalafil</arm_group_label>
    <description>Combination treatment with Macitentan + Tadalafil at baseline</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention, only observation of different groups</intervention_name>
    <arm_group_label>Ambrisentan + Sildenafil</arm_group_label>
    <arm_group_label>Ambrisentan + Tadalafil</arm_group_label>
    <arm_group_label>Bosentan + Sildenafil</arm_group_label>
    <arm_group_label>Bosentan + Tadalafil</arm_group_label>
    <arm_group_label>Macitentan + Sildenafil</arm_group_label>
    <arm_group_label>Macitentan + Tadalafil</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with pulmonary arterial hypertension receiving disease-targeted combination
        therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women ≥ 18 years old

          2. Diagnosis of PAH according to ESC/ERS-guidelines: patients with manifest pulmonary
             arterial hypertension, mean pulmonary arterial pressure ≥25mmHg, measured by right
             heart catheterization.

          3. Combination treatment with ERA (Bosentan, Ambrisentan or Macitentan) and
             PDE-5-Inhibitor (Sildenafil or Tadalafil) for more than 3 months.

        Exclusion Criteria:

          1. Underage patients

          2. Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ekkehard Grünig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thoraxclinic at the University Hospital Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for pulmonary hypertension, Thoraxclinic at the University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.gilead.com/news/press-releases/2014/9/firstline-combination-of-ambrisentan-and-tadalafil-reduces-risk-of-clinical-failure-compared-to-monotherapy-in-pulmonary-arterial-hypertension-outcomes-study.</url>
    <description>First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy in Pulmonary Arterial Hypertension Outcomes Study. Gilead Sciences Inc., 2014. (Accessed 2014-10-13, 2014</description>
  </link>
  <reference>
    <citation>Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009 Oct;30(20):2493-537. doi: 10.1093/eurheartj/ehp297. Epub 2009 Aug 27. Erratum in: Eur Heart J. 2011 Apr;32(8):926.</citation>
    <PMID>19713419</PMID>
  </reference>
  <reference>
    <citation>Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004 Sep 30;351(14):1425-36. Review.</citation>
    <PMID>15459304</PMID>
  </reference>
  <reference>
    <citation>Voelkel NF, Gomez-Arroyo J, Abbate A, Bogaard HJ, Nicolls MR. Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J. 2012 Dec;40(6):1555-65. doi: 10.1183/09031936.00046612. Epub 2012 Jun 27. Review.</citation>
    <PMID>22743666</PMID>
  </reference>
  <reference>
    <citation>Wrishko RE, Dingemanse J, Yu A, Darstein C, Phillips DL, Mitchell MI. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol. 2008 May;48(5):610-8. doi: 10.1177/0091270008315315. Epub 2008 Feb 27.</citation>
    <PMID>18305126</PMID>
  </reference>
  <reference>
    <citation>Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol. 2005 Jul;60(1):107-12.</citation>
    <PMID>15963102</PMID>
  </reference>
  <reference>
    <citation>Weiss J, Theile D, Spalwisz A, Burhenne J, Riedel KD, Haefeli WE. Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells. Biochem Pharmacol. 2013 Jan 15;85(2):265-73. doi: 10.1016/j.bcp.2012.11.020. Epub 2012 Dec 5.</citation>
    <PMID>23219525</PMID>
  </reference>
  <reference>
    <citation>Weiss J, Theile D, Rüppell MA, Speck T, Spalwisz A, Haefeli WE. Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro. Eur J Pharmacol. 2013 Feb 15;701(1-3):168-75. doi: 10.1016/j.ejphar.2013.01.010. Epub 2013 Jan 23.</citation>
    <PMID>23353592</PMID>
  </reference>
  <reference>
    <citation>Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol. 2008 Jan;64(1):43-50. Epub 2007 Nov 27.</citation>
    <PMID>18040672</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>June 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <results_first_submitted>July 19, 2017</results_first_submitted>
  <results_first_submitted_qc>January 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2020</results_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Ekkehard Gruenig</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>March 2015 - September 2015</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bosentan + Sildenafil</title>
          <description>Combination treatment with Bosentan + Sildenafil at baseline
no intervention, only observation of different groups</description>
        </group>
        <group group_id="P2">
          <title>Bosentan + Tadalafil</title>
          <description>Combination treatment with Bosentan + Tadalafil at baseline
no intervention, only observation of different groups</description>
        </group>
        <group group_id="P3">
          <title>Ambrisentan + Sildenafil</title>
          <description>Combination treatment with Ambrisentan + Sildenafil at baseline
no intervention, only observation of different groups</description>
        </group>
        <group group_id="P4">
          <title>Ambrisentan + Tadalafil</title>
          <description>Combination treatment with Ambrisentan + Tadalafil at baseline
no intervention, only observation of different groups</description>
        </group>
        <group group_id="P5">
          <title>Macitentan + Sildenafil</title>
          <description>Combination treatment with Macitentan + Sildenafil at baseline
no intervention, only observation of different groups</description>
        </group>
        <group group_id="P6">
          <title>Macitentan + Tadalafil</title>
          <description>Combination treatment with Macitentan + Tadalafil at baseline
no intervention, only observation of different groups</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="33"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="33"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bosentan + Sildenafil</title>
          <description>Combination treatment with Bosentan + Sildenafil at baseline
no intervention, only observation of different groups</description>
        </group>
        <group group_id="B2">
          <title>Bosentan + Tadalafil</title>
          <description>Combination treatment with Bosentan + Tadalafil at baseline
no intervention, only observation of different groups</description>
        </group>
        <group group_id="B3">
          <title>Ambrisentan + Sildenafil</title>
          <description>Combination treatment with Ambrisentan + Sildenafil at baseline
no intervention, only observation of different groups</description>
        </group>
        <group group_id="B4">
          <title>Ambrisentan + Tadalafil</title>
          <description>Combination treatment with Ambrisentan + Tadalafil at baseline
no intervention, only observation of different groups</description>
        </group>
        <group group_id="B5">
          <title>Macitentan + Sildenafil</title>
          <description>Combination treatment with Macitentan + Sildenafil at baseline
no intervention, only observation of different groups</description>
        </group>
        <group group_id="B6">
          <title>Macitentan + Tadalafil</title>
          <description>Combination treatment with Macitentan + Tadalafil at baseline
no intervention, only observation of different groups</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="21"/>
            <count group_id="B5" value="33"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="125"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="16"/>
                    <measurement group_id="B2" value="56" spread="18"/>
                    <measurement group_id="B3" value="61" spread="19"/>
                    <measurement group_id="B4" value="63" spread="13"/>
                    <measurement group_id="B5" value="65" spread="13"/>
                    <measurement group_id="B6" value="64" spread="21"/>
                    <measurement group_id="B7" value="61" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Characterisation of Medication Levels</title>
        <description>comparison of different combination treatment arms (mean ± standard deviation), measurement of endothelin receptor antagonist plasma concentrations and PDE-5I plasma concentrations, results given es multiple of the expected mean plasma concentration (MOM). Due to technical setup measurement of plasma concentrations of macitentan was not possible.
The expected mean concentration ranges (MOM) refer to data extracted from published plasma concentration-time profiles measured during monotherapy with sildenafil, tadalafil, bosentan, and ambrisentan and served as comparative values. Each individually measured drug concentration was set in proportion to the expected mean concentration and expressed as a multiple of the expected mean (MoM), with values &lt;1 denoting lower and values &gt;1 higher values than the expected mean.</description>
        <time_frame>baseline vs. measurement after 3-6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bosentan + Sildenafil</title>
            <description>Combination treatment with Bosentan + Sildenafil at baseline
no intervention, only observation of different groups</description>
          </group>
          <group group_id="O2">
            <title>Bosentan + Tadalafil</title>
            <description>Combination treatment with Bosentan + Tadalafil at baseline
no intervention, only observation of different groups</description>
          </group>
          <group group_id="O3">
            <title>Ambrisentan + Sildenafil</title>
            <description>Combination treatment with Ambrisentan + Sildenafil at baseline
no intervention, only observation of different groups</description>
          </group>
          <group group_id="O4">
            <title>Ambrisentan + Tadalafil</title>
            <description>Combination treatment with Ambrisentan + Tadalafil at baseline
no intervention, only observation of different groups</description>
          </group>
          <group group_id="O5">
            <title>Macitentan + Sildenafil</title>
            <description>Combination treatment with Macitentan + Sildenafil at baseline
no intervention, only observation of different groups</description>
          </group>
          <group group_id="O6">
            <title>Macitentan + Tadalafil</title>
            <description>Combination treatment with Macitentan + Tadalafil at baseline
no intervention, only observation of different groups</description>
          </group>
        </group_list>
        <measure>
          <title>Characterisation of Medication Levels</title>
          <description>comparison of different combination treatment arms (mean ± standard deviation), measurement of endothelin receptor antagonist plasma concentrations and PDE-5I plasma concentrations, results given es multiple of the expected mean plasma concentration (MOM). Due to technical setup measurement of plasma concentrations of macitentan was not possible.
The expected mean concentration ranges (MOM) refer to data extracted from published plasma concentration-time profiles measured during monotherapy with sildenafil, tadalafil, bosentan, and ambrisentan and served as comparative values. Each individually measured drug concentration was set in proportion to the expected mean concentration and expressed as a multiple of the expected mean (MoM), with values &lt;1 denoting lower and values &gt;1 higher values than the expected mean.</description>
          <units>MOM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ERA concentrations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.54" spread="3.24"/>
                    <measurement group_id="O2" value="2.18" spread="1.23"/>
                    <measurement group_id="O3" value="1.81" spread="0.82"/>
                    <measurement group_id="O4" value="1.53" spread="0.84"/>
                    <measurement group_id="O5" value="NA" spread="NA">measurement of Macitentan Plasma concentrations not possible due to technical limitations</measurement>
                    <measurement group_id="O6" value="NA" spread="NA">measurement of Macitentan Plasma concentrations not possible due to technical limitations</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PDE-5I concentrations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.42"/>
                    <measurement group_id="O2" value="0.89" spread="0.53"/>
                    <measurement group_id="O3" value="1.30" spread="0.97"/>
                    <measurement group_id="O4" value="1.67" spread="0.63"/>
                    <measurement group_id="O5" value="1.16" spread="0.87"/>
                    <measurement group_id="O6" value="1.59" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Medication Adjustment</title>
        <description>Change of medication serum levels after clinically indicated medication adaptation in patients who received Bosentan + Sildenafil in the beginning and changed the ERA to Macitentan
change of mean levels ± standard deviation
frequency of borderline medication serum levels or medication levels out of the therapeutic window The expected mean concentration ranges (MOM) refer to data extracted from published plasma concentration-time profiles measured during monotherapy with sildenafil, tadalafil, bosentan, and ambrisentan and served as comparative values. Each individually measured drug concentration was set in proportion to the expected mean concentration and expressed as a multiple of the expected mean (MoM), with values &lt;1 denoting lower and values &gt;1 higher values than the expected mean.</description>
        <time_frame>baseline vs. measurement 3-6 months after switch</time_frame>
        <population>20 of 39 patients receiving bosentan /sildenafil were switched to macitentan. sildenafil concentrations were compared before and after switch.</population>
        <group_list>
          <group group_id="O1">
            <title>Bosentan / Sildenafil Indicated for Therapy Switch</title>
            <description>patients from bosentan/sildenafil group who showed unsatisfying clinical response to current therapy were switched from bosentan to macitentan. Plasma concentrations were controlled after change of ERA.</description>
          </group>
        </group_list>
        <measure>
          <title>Impact of Medication Adjustment</title>
          <description>Change of medication serum levels after clinically indicated medication adaptation in patients who received Bosentan + Sildenafil in the beginning and changed the ERA to Macitentan
change of mean levels ± standard deviation
frequency of borderline medication serum levels or medication levels out of the therapeutic window The expected mean concentration ranges (MOM) refer to data extracted from published plasma concentration-time profiles measured during monotherapy with sildenafil, tadalafil, bosentan, and ambrisentan and served as comparative values. Each individually measured drug concentration was set in proportion to the expected mean concentration and expressed as a multiple of the expected mean (MoM), with values &lt;1 denoting lower and values &gt;1 higher values than the expected mean.</description>
          <population>20 of 39 patients receiving bosentan /sildenafil were switched to macitentan. sildenafil concentrations were compared before and after switch.</population>
          <units>MOM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sildenafil concentrations before switch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sildenafil concentrations after switch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevance 6 Minute Walking Distance</title>
        <description>Changes of medication levels after adjustment of combination therapy if clinically indicated
correlation with clinical routine parameters indicating clinical disease status</description>
        <time_frame>baseline vs. measurement 3-6 months after switch</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bosentan / Sildenafil Indicated for Therapy Switch</title>
            <description>patients from bosentan/sildenafil group who showed unsatisfying clinical response to current therapy were switched from bosentan to macitentan. Plasma concentrations were controlled after change of ERA.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevance 6 Minute Walking Distance</title>
          <description>Changes of medication levels after adjustment of combination therapy if clinically indicated
correlation with clinical routine parameters indicating clinical disease status</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 minute walking distance before switch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="396" spread="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 minute walking distance after switch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="436" spread="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevance NTproBNP</title>
        <description>Changes of medication levels after adjustment of combination therapy if clinically indicated
correlation with clinical routine parameters indicating clinical disease status</description>
        <time_frame>baseline vs. measurement after 3-6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bosentan / Sildenafil Indicated for Therapy Switch</title>
            <description>patients from bosentan/sildenafil group who showed unsatisfying clinical response to current therapy were switched from bosentan to macitentan. Plasma concentrations were controlled after change of ERA.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevance NTproBNP</title>
          <description>Changes of medication levels after adjustment of combination therapy if clinically indicated
correlation with clinical routine parameters indicating clinical disease status</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NTproBNP before switch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2204" spread="3823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NTproBNP after switch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1181" spread="2899"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevance Echocardiography Systolic Pulmonary Arterial Pressure (sPAP)</title>
        <description>Changes of medication levels after adjustment of combination therapy if clinically indicated
correlation with clinical routine parameters indicating clinical disease status</description>
        <time_frame>baseline vs. measurement after 3-6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bosentan / Sildenafil Indicated for Therapy Switch</title>
            <description>patients from bosentan/sildenafil group who showed unsatisfying clinical response to current therapy were switched from bosentan to macitentan. Plasma concentrations were controlled after change of ERA.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevance Echocardiography Systolic Pulmonary Arterial Pressure (sPAP)</title>
          <description>Changes of medication levels after adjustment of combination therapy if clinically indicated
correlation with clinical routine parameters indicating clinical disease status</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sPAP before switch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.6" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sPAP after switch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.2" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevance Echocardiography Tricuspid Annular Plane Systolic Excursion (TAPSE)</title>
        <description>Changes of medication levels after adjustment of combination therapy if clinically indicated
correlation with clinical routine parameters indicating clinical disease status</description>
        <time_frame>baseline vs. measurement after 3-6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bosentan / Sildenafil Indicated for Therapy Switch</title>
            <description>patients from bosentan/sildenafil group who showed unsatisfying clinical response to current therapy were switched from bosentan to macitentan. Plasma concentrations were controlled after change of ERA.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevance Echocardiography Tricuspid Annular Plane Systolic Excursion (TAPSE)</title>
          <description>Changes of medication levels after adjustment of combination therapy if clinically indicated
correlation with clinical routine parameters indicating clinical disease status</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAPSE before switch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TAPSE after switch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevance Blood Gas Analysis Oxygen Saturation</title>
        <description>Changes of medication levels after adjustment of combination therapy if clinically indicated
correlation with clinical routine parameters indicating clinical disease status</description>
        <time_frame>baseline vs. measurement after 3-6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bosentan / Sildenafil Indicated for Therapy Switch</title>
            <description>patients from bosentan/sildenafil group who showed unsatisfying clinical response to current therapy were switched from bosentan to macitentan. Plasma concentrations were controlled after change of ERA.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevance Blood Gas Analysis Oxygen Saturation</title>
          <description>Changes of medication levels after adjustment of combination therapy if clinically indicated
correlation with clinical routine parameters indicating clinical disease status</description>
          <units>% oxygen saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>oxygen saturation before switch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.2" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>oxygen saturation after switch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.0" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>this is a non-interventional, cross-sectional cohort study. All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bosentan + Sildenafil</title>
          <description>Combination treatment with Bosentan + Sildenafil at baseline
no intervention, only observation of different groups</description>
        </group>
        <group group_id="E2">
          <title>Bosentan + Tadalafil</title>
          <description>Combination treatment with Bosentan + Tadalafil at baseline
no intervention, only observation of different groups</description>
        </group>
        <group group_id="E3">
          <title>Ambrisentan + Sildenafil</title>
          <description>Combination treatment with Ambrisentan + Sildenafil at baseline
no intervention, only observation of different groups</description>
        </group>
        <group group_id="E4">
          <title>Ambrisentan + Tadalafil</title>
          <description>Combination treatment with Ambrisentan + Tadalafil at baseline
no intervention, only observation of different groups</description>
        </group>
        <group group_id="E5">
          <title>Macitentan + Sildenafil</title>
          <description>Combination treatment with Macitentan + Sildenafil at baseline
no intervention, only observation of different groups</description>
        </group>
        <group group_id="E6">
          <title>Macitentan + Tadalafil</title>
          <description>Combination treatment with Macitentan + Tadalafil at baseline
no intervention, only observation of different groups</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>small sample size. Due to the fact that currently no established therapeutic plasma concentration ranges exist, no conclusion can be drawn whether lower or higher concentrations lead to treatment failure or adverse events.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Professor Dr. med. Ekkehard Grünig</name_or_title>
      <organization>Centre for pulmonary hypertension of the Thoraxclinic at the University Hospital Heidelberg</organization>
      <phone>+4962213968053</phone>
      <email>ekkehard.gruenig@med.uni-heidelberg.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

